Klinik, Diagnostik und Therapie der Mykoplasmen-Pneumonie

Zusammenfassung

Mykoplasmen sind ein fester Bestandteil des Erregerspektrums bei ambulant erworbener Pneumonie. Bei schweren Verläufen können die extrapulmonalen Manifestationen der Erkrankung im Vordergrund stehen. Der Nachweis der Infektion erfolgt im Regelfall erst verzögert über die Serologie. Eine kalkulierte Therapie der ambulant erworbenen Pneumonie muss deshalb, vor allem bei jüngeren Patienten mit interstitiellen Infiltraten, auch Mykoplasmen miteinbeziehen. Makrolide sind die am häufigsten eingesetzten Antibiotika bei Mykoplasmeninfektionen, alternativ stehen Ketolide, Fluorchinolone sowie Tetracycline zur Verfügung.

Abstract

Mycoplasma pneumoniae is a common respiratory pathogen in community acquired pneumonia. In severe cases extrapulmonary manifestations of the disease may be prominent. Proof of infection is found, though usually delayed, through serologic methods. A calculated therapy of community acquired pneumonia, especially in younger patients with interstitial infiltrates, should therefore include effective treatment for Mycoplasma pneumoniae. Macrolide antibiotics are the most commonly used antibiotics in the treatment of mycoplasma infection, alternatives include ketolides, quinolones and tetracyclines.

Literatur

• 1 Reimann H A. An acute infection of the respiratory tract with atypical pneumonia. A disease entity probably caused by a filtrable virus.  JAMA. 1938;  111 2377-2384
• 2 Luby J P. Pneumonia caused by Mycoplasma pneumoniae infection.  Clin Chest Med. 1991;  12 237-244
• 3 Clyde W A Jr. Clinical overview of typical mycoplasma pneumoniae infections.  Clin Infect Dis. 1993;  17 S32-36
• 4 Lieberman D, Schlaeffer F, Lieberman D. et al . Mycoplasma pneumoniae community-acquired pneumonia: a review of 101 hospitalized adult patients.  Respiration. 1996;  63 261-266
• 5 Feizi T, Loveless R W. Carbohydrate recognition by Mycoplasma pneumoniae and pathologic consequences.  Am J Respir Crit Care Med. 1996;  154 S133-136
• 6 Baseman J B, Reddy S P, Dallo S F. Interplay between mycoplasma surface proteins, airway cells, and the protean manifestations of mycoplasma-mediated human infections.  Am J Respir Crit Care Med. 1996;  154 S137-144
• 7 Marston B J, Plouffe J F, File T M. et al . Incidence of community-acquired pneumonia requiring hospitalization.  Arch Intern Med. 1997;  157 1709-1718
• 8 Mundy L M, Oldach D, Auwaerter P G. et al . Implications for macrolide treatment in community-acquired pneumonia.  Chest. 1998;  113 1201-1206
• 9 Sopena N, Sabria M, Pedro-Botet M L. et al . Prospective study of community acquired pneumonia of bacterial etiology in adults.  Eur J Clin Microbiol Infect Dis. 1999;  18 852-858
• 10 Foy H M, Kenny G E, Cooney M K. et al . Long-term epidemiology of infections with Mycoplasma pneumoniae.  J Infect Dis. 1979;  139 681-687
• 11 Mansel J K, Rosenow E C 3rd, Smith T F. et al . Mycoplasma pneumoniae pneumonia.  Chest. 1989;  95 639-646
• 12 Lieberman D, Lieberman D, Printz S. et al . Atypical pathogen infection in adults with acute exacerbation of bronchial asthma.  Am J Resp Crit Care Med. 2003;  167 406-410
• 13 Martin R E, Bates J H. Atypical pneumonia.  Infect Dis Clin North Am. 1991;  5 585-601
• 14 Tay Y K, Huff J C, Weston W L. Mycoplasma pneumoniae is associated with Stevens-Johnson syndrome, not erythema multiforme (von Hebra).  J Am Acad Dermatol. 1996;  35 757-760
• 15 Koskiniemi M. CNS manifestations associated with Mycoplasma pneumoniae infections: summary of cases at the University of Helsinki and review.  Clin Infect Dis. 1993;  17 S52-57
• 16 Vitullo B B, O'Regan S, de Chadarevian J P. et al . Mycoplasma pneumoniae associated with acute glomerulonephritis.  Nephron. 1978;  21 284-288
• 17 Berger R P, Wadowksy R M. Rhabdomyolysis associated with infection by Mycoplasma pneumoniae: a case report.  Pediatrics. 2000;  105 (2) 433-436
• 18 Joo C U, Kim J S, Han Y M. Mycoplasma pneumoniae induced popliteal artery thrombosis treated with urokinase.  Postgrad Med J 2001. Nov;  77 (913) 723-724
• 19 Mizukane R, Kadota Ji J, Yamaguchi T. et al . An elderly patient with hemophagocytic syndrome due to severe mycoplasma pneumonia with marked hypercytokinemia.  Respiration. 2002;  69 (1) 87-91
• 20 Subcommittee of the Research Committee of the British Thoracic Society and the Public Health Laboratory Service . Community-acquired pneumonia in adults in British hospitals in 1982 - 83: a survey of aetiology, mortality, prognostic factors and outcome.  Q J Med. 1987;  62 195-220
• 21 Baer G, Engelcke G, Abele-Horn M. et al . Role of Chlamydia pneumoniae and Mycoplasma pneumoniae as causative agents of community-acquired pneumonia in hospitalised children and adolescents.  Eur J Clin Microbiol Infect Dis. 2003;  22 742-745
• 22 Kenny G E, Kaiser G G, Cooney M K. et al . Diagnosis of Mycoplasma pneumoniae pneumonia: sensitivities and specificity of serology with lipid antigen and isolation of the organism on soy peptone medium for identification of infections.  J Clin Microbiol. 1990;  28 2087-2093
• 23 Templeton K E, Scheltinga S A, Graffelman A W. et al . Comparison and evaluation of real-time PCR, real-time nucleic acid sequence-based amplification, conventional PCR, and serology for diagnosis of mycoplasma pneumoniae.  J Clin Microbiol. 2003;  41 4366-4371
• 24 Jacobs E. Serological diagnosis of Mycoplasma pneumoniae infections: a critical review of current procedures.  Clin Infect Dis. 1993;  17 S79-82
• 25 Thacker W L, Talkington D F. Analysis of complement fixation and commercial enzyme immunoassays for detection of antibodies to Mycoplasma pneumoniae in human serum.  Clin Diagn Lab Immunol. 2000;  7 778-780
• 26 Tjhie J H, van Kuppeveld F J, Roosendaal R. et al . Direct PCR enables detection of Mycoplasma pneumoniae in patients with respiratory tract infections.  J Clin Microbiol. 1994;  32 11-16
• 27 Blackmore T K, Reznikov M, Gordon D L. Clinical utility of the polymerase chain reaction to diagnose Mycoplasma pneumoniae infection.  Pathology. 1995;  27 177-181
• 28 Ieven M, Goossens H. Relevance of nucleic acid amplification techniques for diagnosis of respiratory tract infections in the clinical laboratory.  Clin Microbiol Rev. 1997;  10 242-256
• 29 Daxboeck F, Krause R, Wenisch C. Laboratory diagnosis of mycoplasma pneumoniae infection.  Clin Microbiol Infect. 2003;  9 263-273
• 30 Welti M, Jaton K, Altwegg M. et al . Development of a multiplex real-time quantitative PCR assay to detect Chlamydia pneumoniae, Legionella pneumophila and Mycoplasma pneumoniae in respiratory tract secretions.  Diagn Microbiol Infect Dis. 2003;  45 85-95
• 31 Loens K, Ursi D, Goossens H. et al . Molecular diagnosis of Mycoplasma pneumoniae respiratory tract infections.  J Clin Microbiol. 2003;  41 4915-4923
• 32 Schaberg T, Dalhoff K, Ewig S. et al . Empfehlungen zur Therapie der ambulant erworbenen Pneumonie. Deutsche Gesellschaft für Pneumologie.  Pneumologie. 1998;  52 450-462
• 33 Vogel F, Worth H, Adam D. et al . Rationale Therapie bakterieller Atemwegsinfektionen. Empfehlungen einer Expertengruppe der Paul-Ehrlich-Gesellschaft für Chemotherapie e. v. und der Deutschen Atemwegsliga.  Chemotherapie Journal. 2000;  1 3-23
• 34 Hammerschlag M R. Mycoplasma pneumoniae infections.  Curr Opin Infect Dis. 2001 Apr;  14 (2) 181-186
• 35 Taylor-Robinson D, Bebear C. Antibiotic susceptibilities of mycoplasmas and treatment of mycoplasmal infections.  J Antimicrob Chemother. 1997;  40 622-630
• 36 Feikin D R, Moroney J F, Talkington D F. et al . An outbreak of acute respiratory disease caused by Mycoplasma pneumoniae and adenovirus at a federal service training academy: new implications from an old scenario.  Clin Infect Dis. 1999;  29 1545-1550
• 37 Klausner J D, Passaro D, Rosenberg J. et al . Enhanced control of an outbreak of Mycoplasma pneumoniae pneumonia with azithromycin prophylaxis.  J Infect Dis. 1998;  177 161-166
• 38 Lode H, Allewelt M. Role of newer fluoroquinolones in lower respiratory tract infections.  J Antimicrob Chemother. 2002;  50 151-154
• 39 Yamaguchi T, Hirakata Y, Izumikawa K. et al . In vitro activity of telithromycin (HMR 3647), a new ketolide, against clinical isolates of Mycoplasma pneumoniae in Japan.  Antimicrob Agents Chemother. 2000;  44 1381-1382
• 40 Carbon C, Moola S, Velancsics I. Telithromycin 800 mg once daily for seven to ten days is an effective and well-tolerated treatment for community-acquired pneumonia.  Clin Microbiol Infect. 2003;  9 691-703
• 41 Lorenz J. Clinical efficacy of new antibacterial therapies in at-risk populations.  J Infect. 2002 Feb ;  44 Suppl A 25-30
• 42 Ikejima H, Yamamoto H, Ishida K. et al . Evaluation of in-vitro activity of new quinolones, macrolides, and minocycline against Mycoplasma pneumoniae.  J Infect Chemother. 2000;  6 148-150
• 43 Waites K B, Crabb D M, Bing X. et al . In vitro susceptibilities to and bactericidal activities of garenoxacin (BMS-284 756) and other antimicrobial agents against human mycoplasmas and ureaplasmas.  Antimicrob Agents Chemother. 2003;  47 161-165
• 44 Bebear C M, Renaudin H, Bryskier A. et al . Comparative activities of telithromycin (HMR 3647), levofloxacin, and other antimicrobial agents against human mycoplasmas.  Antimicrob Agents Chemother. 2000;  44 1980-1982
• 45 Kenny G E, Cartwright F D. Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin, and telithromycin compared to their susceptibilities to reference macrolides, tetracyclines, and quinolones.  Antimicrob Agents Chemother. 2001;  45 2604-2608

Bereits publizierte Beiträge zu dieser Serie:

• 41 Diagnostik und Therapie der Legionellen-Pneumonie.  Pneumologie. 2002;  56 695-703
• 42 Diagnostik, Therapie und Prävention der Influenza (Virusgrippe).  Pneumologie. 2003;  57 27-33
• 43 Klinisches Bild, Diagnostik und Therapie der Chlamydien-Pneumonie.  Pneumologie. 2003;  57 449-458